Flputnam Investment Management Co. Buys 236,586 Shares of Boston Scientific Corporation $BSX

Flputnam Investment Management Co. grew its stake in Boston Scientific Corporation (NYSE:BSX) by 237.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 336,059 shares of the medical equipment provider’s stock after acquiring an additional 236,586 shares during the period. Flputnam Investment Management Co.’s holdings in Boston Scientific were worth $32,809,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its position in Boston Scientific by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after purchasing an additional 2,545,381 shares during the last quarter. State Street Corp boosted its position in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after acquiring an additional 622,602 shares during the last quarter. Norges Bank acquired a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $2,089,937,000. Finally, Invesco Ltd. raised its position in shares of Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock valued at $1,810,022,000 after acquiring an additional 226,578 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on BSX. UBS Group reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday. BTIG Research reaffirmed a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Friday, November 21st. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Friday, October 17th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Royal Bank Of Canada upped their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $124.85.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: RBC Capital continues to rate BSX as an “outperform,” reinforcing buy-side support from a major bank and likely helping demand for shares. RBC Capital maintains Boston Scientific (BSX) outperform recommendation
• Positive Sentiment: Royal Bank of Canada analyst commentary suggests upside ahead for BSX, adding another institutional voice expecting price appreciation. This supports the bullish narrative among analysts. Boston Scientific (NYSE:BSX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
• Positive Sentiment: Truist reaffirmed a “buy” rating on BSX, signaling continued analyst confidence even as the firm updated its outlook—this helps underwrite medium-term investor sentiment. Truist Securities maintains Boston Scientific (BSX) buy recommendation
• Positive Sentiment: Zacks highlights BSX’s global expansion push — R&D, AI-driven manufacturing and a focused Emerging Markets effort targeting $1B+ revenue in China for 2025 — a strategic growth catalyst that supports longer-term upside. Boston Scientific’s Global Expansion: What’s Behind the Growth?
• Neutral Sentiment: Options flow is active around BSX; Benzinga’s options-focused piece notes positioning that can amplify intraday moves but doesn’t definitively indicate directional conviction from fundamental investors. Watch open interest and strike concentration for short-term signals. Decoding Boston Scientific’s Options Activity: What’s the Big Picture?
• Neutral Sentiment: Informational pieces recap BSX’s multi-year performance; useful for context but unlikely to move the stock today. These highlight solid historical returns that underpin investor confidence. Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 5 Years
• Neutral Sentiment: Short-term market commentary notes BSX outperformed earlier sessions; useful for momentum traders but not a standalone fundamental driver. Boston Scientific (BSX) Advances While Market Declines
• Negative Sentiment: Truist cut its price target from $130 to $120 — a downward revision that may cap near-term upside and pressures sentiment despite the maintained “buy” rating. That target trim likely explains some of the selling pressure today. BSX price target lowered by Truist

Boston Scientific Trading Down 0.5%

NYSE:BSX opened at $95.61 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The business’s 50-day simple moving average is $98.64 and its 200-day simple moving average is $101.26. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The stock has a market capitalization of $141.74 billion, a PE ratio of 51.13, a price-to-earnings-growth ratio of 1.93 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the company posted $0.63 EPS. The business’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 143,095 shares of company stock worth $14,228,950 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.